These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33071786)

  • 1. Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome.
    Rubsamen R; Burkholz S; Massey C; Brasel T; Hodge T; Wang L; Herst C; Carback R; Harris P
    Front Pharmacol; 2020; 11():574703. PubMed ID: 33071786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
    Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
    J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
    Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
    J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies.
    Ilinykh PA; Shen X; Flyak AI; Kuzmina N; Ksiazek TG; Crowe JE; Bukreyev A
    J Virol; 2016 Apr; 90(8):3890-3901. PubMed ID: 26819310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions.
    Kuzmin IV; Schwarz TM; Ilinykh PA; Jordan I; Ksiazek TG; Sachidanandam R; Basler CF; Bukreyev A
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28122983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment.
    Lau SKP; Lau CCY; Chan KH; Li CPY; Chen H; Jin DY; Chan JFW; Woo PCY; Yuen KY
    J Gen Virol; 2013 Dec; 94(Pt 12):2679-2690. PubMed ID: 24077366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40.
    Yu DS; Weng TH; Shen L; Wu XX; Hu CY; Wang FXC; Wu ZG; Wu HB; Wu NP; Li LJ; Yao H
    Cell Physiol Biochem; 2018; 50(3):1055-1067. PubMed ID: 30355918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
    Pallua N; Low JF; von Heimburg D
    Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6 signaling blockade treatment for cytokine release syndrome in COVID-19 (Review).
    Chen JJ; Zhang LN; Hou H; Xu L; Ji K
    Exp Ther Med; 2021 Jan; 21(1):24. PubMed ID: 33262810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the mechanism of action of anti-human interleukin-6 and anti-human interleukin-6 receptor-neutralising monoclonal antibodies.
    Kalai M; Montero-Julian FA; Brakenhoff JP; Fontaine V; De Wit L; Wollmer A; Brailly H; Content J; Grötzinger J
    Eur J Biochem; 1997 Nov; 249(3):690-700. PubMed ID: 9395315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between TIM-1 and NPC1 Is Important for Cellular Entry of Ebola Virus.
    Kuroda M; Fujikura D; Nanbo A; Marzi A; Noyori O; Kajihara M; Maruyama J; Matsuno K; Miyamoto H; Yoshida R; Feldmann H; Takada A
    J Virol; 2015 Jun; 89(12):6481-93. PubMed ID: 25855742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and Characterization of Anti-Filovirus Nucleoprotein Monoclonal Antibodies.
    Rahim MN; Wang M; Wang T; He S; Griffin BD; Kobasa D; Yang R; Du Z; Qiu X
    Viruses; 2019 Mar; 11(3):. PubMed ID: 30875741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis.
    Terabe F; Fujimoto M; Serada S; Shinzaki S; Iijima H; Tsujii M; Hayashi N; Nomura S; Kawahata H; Jang MH; Miyasaka M; Mihara M; Ohsugi Y; Kishimoto T; Naka T
    Inflamm Bowel Dis; 2011 Feb; 17(2):491-502. PubMed ID: 20602470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)?
    Liu D; Zhang T; Wang Y; Xia L
    Front Med (Lausanne); 2020; 7():571597. PubMed ID: 33195318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects.
    Chavin KD; Qin L; Lin J; Kaplan AJ; Bromberg JS
    Transplantation; 1993 Apr; 55(4):901-8. PubMed ID: 8097344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niemann-pick C1 is essential for ebolavirus replication and pathogenesis in vivo.
    Herbert AS; Davidson C; Kuehne AI; Bakken R; Braigen SZ; Gunn KE; Whelan SP; Brummelkamp TR; Twenhafel NA; Chandran K; Walkley SU; Dye JM
    mBio; 2015 May; 6(3):e00565-15. PubMed ID: 26015498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
    Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
    J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.
    Chen F; Teachey DT; Pequignot E; Frey N; Porter D; Maude SL; Grupp SA; June CH; Melenhorst JJ; Lacey SF
    J Immunol Methods; 2016 Jul; 434():1-8. PubMed ID: 27049586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6 blockade attenuates the development of murine sclerodermatous chronic graft-versus-host disease.
    Le Huu D; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
    J Invest Dermatol; 2012 Dec; 132(12):2752-61. PubMed ID: 22810302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.
    Menicucci AR; Jankeel A; Feldmann H; Marzi A; Messaoudi I
    mBio; 2019 May; 10(3):. PubMed ID: 31138743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.